Related Experiment Video
Updated: Sep 13, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Primary Choriocarcinoma of Colon: Case Report and Literature Review
Naoto Okazaki1, Akira Tanaka2, Masanori Yasuda3
1Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan.
Abstract:
Primary colorectal choriocarcinoma is extremely rare with only 35 cases described in the literature during over 40 years. The neoplasm is characterized by biphasic tumor growth composed of adenocarcinomatous and choriocarcinomatous differentiation. Diagnostic elusiveness, aggressive nature and lack of established treatment make the prognosis extremely poor, and most patients die during the first year after diagnosis. We present a 66-year-old man with a primary choriocarcinoma of the transverse colon presenting with peritoneal metastasis and acute colonic obstruction. The patient was treated with systemic three-drug chemotherapy (mFOLFOXIRI: 5-fluorouracil/leucovorin + oxaliplatin + irinotecan) in combination with bevacizumab, a highly active regimen for metastatic colorectal adenocarcinoma. Tumor shrinkage was accompanied by a decrease of mononucleated trophoblast-like carcinoma cells in an endoscopic biopsy during the treatment, and the symptoms of disease were relieved within a quite short period of therapy, though rapid regrowth associated with serum beta human chorionic gonadotropin escalation occurred following discontinuation of therapy. The patient died 8 months after the initial diagnosis. Although our patient survived longer than the median survival period documented in the literature, further cases will need to be examined in the future to establish whether this antitumor treatment is effective to prolong survival.

